Resumen

ALCANTARA MONTERO, A.  y  GONZALEZ CURADO, A.. Lacosamide in the treatment of neuropathic pain. Rev. Soc. Esp. Dolor [online]. 2016, vol.23, n.6, pp.316-325. ISSN 1134-8046.

Most of the clinical practice guidelines consulted agree that tricyclics, dual (venlafaxine/duloxetine) antidepressants, gabapentin/pregabalin antiepileptics, lidocaine 5 % patches and capsaicin 8 % patches are the first-line drugs in the treatment of peripheral neuropathic pain, being tramadol and some strong opioids (morphine, oxycodone and tapentadol) second-line drugs treatment. Moreover, the prevalence of neuropathic pain refractory to treatment is about 1,5 % of the population, so that an estimated 50 % of patients not responding to prescribed treatment. There are other antiepileptics who not have neuropathic pain indication by regulatory agencies, such as lamotrigine, topiramate or oxcarbazepine, but are used in routine clinical practice off-label. Although not approved the use of lacosamide in the treatment of neuropathic pain, some authors believe that could be a good option for patients who do not respond to standard treatments. The following article summarizes the main pharmacological characteristics of lacosamide as well as the literature available in neuropathic pain.

Palabras clave : Lacosamide; neuropathic pain.

        · resumen en Español     · texto en Español     · Español ( pdf )